Organon presents VTAMA analysis: Organon stock gains 1.16 percent

Published on 10/01/2026 at 22:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 1.60 billion in the second quarter of 2026, matching consensus. Organon stock costs EUR 12.21 after EUR 12.07, plus 1.16 percent.

OGN, US68622V1061, Illustration mit AI erstellt.

Organon (ISIN US68622V1061) was trading at EUR 12.21 at Lang & Schwarz on October 1, 2026 at 10:38 p.m. CEST, up 1.16 percent versus the prior close of EUR 12.07. The company announced on October 1 that it will present new real-world data for VTAMA, its tapinarof cream, at the 2026 Fall Clinical Dermatology Conference, according to Business Wire.

VTAMA data adds a pipeline test

The analysis covers patients with atopic dermatitis treated with VTAMA cream, 1%, and evaluates physician-reported body surface area and physician global assessment outcomes alongside patient-reported itch scores. The findings are scheduled for display at the conference in Las Vegas, giving Organon a new evidence point for a product already used in plaque psoriasis and atopic dermatitis.

Business Wire says the analysis is intended to represent one of the first large-scale real-world effectiveness analyses of VTAMA in atopic dermatitis. That distinction matters because real-world outcomes can complement controlled clinical-trial evidence as Organon expands the product's commercial role.

Second-quarter figures set the baseline

Organon's second-quarter 2026 revenue was USD 1.60 billion, matching the USD 1.60 billion consensus estimate, while earnings per share came in at USD 0.85 against USD 0.85 expected, according to GetSignal. The quarter therefore supplied an in-line operating reference rather than a large earnings surprise.

MarketBeat lists a Reduce consensus based on five Hold ratings and two Sell ratings, with an average USD 11.40 price target, according to MarketBeat. The target sits below the latest USD 13.71 primary-market quote, keeping valuation and execution in tension with the pipeline updates.

Stock gains while analysts stay cautious

Lang & Schwarz showed Organon stock at EUR 12.21 on October 1, 2026 at 10:38 p.m. CEST, a plus 1.16 percent move from the EUR 12.07 prior close. The same-day market backdrop included a 52-week range of USD 5.69 to USD 13.79 and market capitalization of USD 3.6 billion.